Evotec to Use PhosphoScout Platform in Oncology Biomarker Alliance with Roche
July 01, 2011
Evotec to Use PhosphoScout Platform in Oncology Biomarker Alliance with Roche
The deal marks the first pharma alliance for Evotec since it acquired Kinaxo in mid-April in a deal worth up to $23 million.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Kinaxo, Takeda Ink Second Collaboration for Phosphoproteomics Research
March 18, 2011 / ProteoMonitor - AstraZeneca Taps Kinaxo to Conduct Mass Spec PTM Studies for Oncology Drug Development
January 7, 2011 / ProteoMonitor - GSK to Buy Cellzome for $99M as Pharma Interest in Chemical Proteomics Continues to Build
May 18, 2012 / ProteoMonitor - UNC Team Takes Proteomic Approach to Study Drug Resistance in Triple-Negative Breast Cancer
April 20, 2012 / ProteoMonitor - Yale Researcher Suggests More Focus on EGFR Isoforms Needed in Development of Antibody-Based Drugs
May 20, 2011 / ProteoMonitor